Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Intracellular cytidine deaminase regulates gemcitabine metabolism in pancreatic cancer cell lines.

Bjånes TK, Jordheim LP, Schjøtt J, Kamceva T, Cros-Perrial E, Langer A, de Garibay GR, Kotopoulis S, McCormack E, Riedel B.

Drug Metab Dispos. 2019 Dec 23. pii: dmd.119.089334. doi: 10.1124/dmd.119.089334. [Epub ahead of print]

2.

Rationally designed hyaluronic acid-based nano-complexes for pentamidine delivery.

Carton F, Chevalier Y, Nicoletti L, Tarnowska M, Stella B, Arpicco S, Malatesta M, Jordheim LP, Briançon S, Lollo G.

Int J Pharm. 2019 Sep 10;568:118526. doi: 10.1016/j.ijpharm.2019.118526. Epub 2019 Jul 16.

PMID:
31323370
3.

Synthesis of Substituted 5'-Aminoadenosine Derivatives and Evaluation of Their Inhibitory Potential toward CD73.

Ghoteimi R, Nguyen VT, Rahimova R, Grosjean F, Cros-Perrial E, Uttaro JP, Mathé C, Chaloin L, Jordheim LP, Peyrottes S.

ChemMedChem. 2019 Aug 6;14(15):1431-1443. doi: 10.1002/cmdc.201900348. Epub 2019 Jul 25.

PMID:
31264794
4.

Synthesis and biological evaluation of zinc chelating compounds as metallo-β-lactamase inhibitors.

Kildahl-Andersen G, Schnaars C, Prandina A, Radix S, Le Borgne M, Jordheim LP, Gjøen T, Andresen AMS, Lauksund S, Fröhlich C, Samuelsen Ø, Rongved P, Åstrand OAH.

Medchemcomm. 2019 Mar 8;10(4):528-537. doi: 10.1039/c8md00578h. eCollection 2019 Apr 1.

PMID:
31057732
5.

Lead optimization and biological evaluation of fragment-based cN-II inhibitors.

Guillon R, Rahimova R, Preeti, Egron D, Rouanet S, Dumontet C, Aghajari N, Jordheim LP, Chaloin L, Peyrottes S.

Eur J Med Chem. 2019 Apr 15;168:28-44. doi: 10.1016/j.ejmech.2019.02.040. Epub 2019 Feb 14.

PMID:
30798051
6.

Expanding the clinical relevance of the 5'-nucleotidase cN-II/NT5C2.

Jordheim LP.

Purinergic Signal. 2018 Dec;14(4):321-329. doi: 10.1007/s11302-018-9627-2. Epub 2018 Oct 25. Review.

7.

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent.

Grasselly C, Denis M, Bourguignon A, Talhi N, Mathe D, Tourette A, Serre L, Jordheim LP, Matera EL, Dumontet C.

Front Immunol. 2018 Oct 9;9:2100. doi: 10.3389/fimmu.2018.02100. eCollection 2018.

8.

CD73 inhibition by purine cytotoxic nucleoside analogue-based diphosphonates.

Dumontet C, Peyrottes S, Rabeson C, Cros-Perrial E, Géant PY, Chaloin L, Jordheim LP.

Eur J Med Chem. 2018 Sep 5;157:1051-1055. doi: 10.1016/j.ejmech.2018.08.035. Epub 2018 Aug 17.

PMID:
30176535
9.

Polymeric nanocapsules as drug carriers for sustained anticancer activity of calcitriol in breast cancer cells.

Nicolas S, Bolzinger MA, Jordheim LP, Chevalier Y, Fessi H, Almouazen E.

Int J Pharm. 2018 Oct 25;550(1-2):170-179. doi: 10.1016/j.ijpharm.2018.08.022. Epub 2018 Aug 14.

PMID:
30118832
10.

Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells.

Jordheim LP, Chettab K, Cros-Perrial E, Matera EL, Dumontet C.

Pharmacology. 2018;102(3-4):161-168. doi: 10.1159/000491587. Epub 2018 Jul 26.

PMID:
30048976
11.

Cytosolic 5'-Nucleotidase II Silencing in a Human Lung Carcinoma Cell Line Opposes Cancer Phenotype with a Concomitant Increase in p53 Phosphorylation.

Pesi R, Petrotto E, Colombaioni L, Allegrini S, Garcia-Gil M, Camici M, Jordheim LP, Tozzi MG.

Int J Mol Sci. 2018 Jul 20;19(7). pii: E2115. doi: 10.3390/ijms19072115.

12.

Synthesis and Preclinical Evaluation of TPA-Based Zinc Chelators as Metallo-β-lactamase Inhibitors.

Schnaars C, Kildahl-Andersen G, Prandina A, Popal R, Radix S, Le Borgne M, Gjøen T, Andresen AMS, Heikal A, Økstad OA, Fröhlich C, Samuelsen Ø, Lauksund S, Jordheim LP, Rongved P, Åstrand OAH.

ACS Infect Dis. 2018 Sep 14;4(9):1407-1422. doi: 10.1021/acsinfecdis.8b00137. Epub 2018 Aug 2.

PMID:
30022668
13.

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer.

Toffalorio F, Santarpia M, Radice D, Jaramillo CA, Spitaleri G, Manzotti M, Catania C, Jordheim LP, Pelosi G, Peters GJ, Tibaldi C, Funel N, Spaggiari L, de Braud F, De Pas T, Giovannetti E.

Oncotarget. 2018 Feb 16;9(23):16437-16450. doi: 10.18632/oncotarget.24505. eCollection 2018 Mar 27.

14.

Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface.

Rahimova R, Fontanel S, Lionne C, Jordheim LP, Peyrottes S, Chaloin L.

PLoS Comput Biol. 2018 Jan 29;14(1):e1005943. doi: 10.1371/journal.pcbi.1005943. eCollection 2018 Jan.

15.

Functions of the multi-interacting protein KIDINS220/ARMS in cancer and other pathologies.

Raza MZ, Allegrini S, Dumontet C, Jordheim LP.

Genes Chromosomes Cancer. 2018 Mar;57(3):114-122. doi: 10.1002/gcc.22514. Epub 2017 Dec 20. Review.

PMID:
29181864
16.

Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b/ICAM-1 binding.

Hirz T, Matera EL, Chettab K, Jordheim LP, Mathé D, Evesque A, Esmenjaud J, Salles G, Dumontet C.

Oncotarget. 2017 Aug 18;8(42):72818-72834. doi: 10.18632/oncotarget.20350. eCollection 2017 Sep 22.

17.

The cytosolic 5'-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells.

Bricard G, Cadassou O, Cassagnes LE, Cros-Perrial E, Payen-Gay L, Puy JY, Lefebvre-Tournier I, Tozzi MG, Dumontet C, Jordheim LP.

Oncotarget. 2017 Jun 27;8(40):67380-67393. doi: 10.18632/oncotarget.18653. eCollection 2017 Sep 15.

18.

Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells.

Puy JY, Jordheim LP, Cros-Perrial E, Dumontet C, Peyrottes S, Lefebvre-Tournier I.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 15;1053:101-110. doi: 10.1016/j.jchromb.2017.03.024. Epub 2017 Mar 24.

PMID:
28415014
19.

Stably transfected adherent cancer cell models with decreased expression of 5'-nucleotidase cN-II.

Bricard G, Cros-Perrial E, Machon C, Dumontet C, Jordheim LP.

Nucleosides Nucleotides Nucleic Acids. 2016 Dec;35(10-12):604-612.

PMID:
27906612
20.

Beta-hydroxyphosphonate ribonucleoside analogues derived from 4-substituted-1,2,3-triazoles as IMP/GMP mimics: synthesis and biological evaluation.

Nguyen Van T, Hospital A, Lionne C, Jordheim LP, Dumontet C, Périgaud C, Chaloin L, Peyrottes S.

Beilstein J Org Chem. 2016 Jul 18;12:1476-86. doi: 10.3762/bjoc.12.144. eCollection 2016.

21.

The druggability of intracellular nucleotide-degrading enzymes.

Rampazzo C, Tozzi MG, Dumontet C, Jordheim LP.

Cancer Chemother Pharmacol. 2016 May;77(5):883-93. doi: 10.1007/s00280-015-2921-6. Epub 2015 Nov 27. Review.

PMID:
26614508
22.

Identification of Noncompetitive Inhibitors of Cytosolic 5'-Nucleotidase II Using a Fragment-Based Approach.

Marton Z, Guillon R, Krimm I, Preeti, Rahimova R, Egron D, Jordheim LP, Aghajari N, Dumontet C, Périgaud C, Lionne C, Peyrottes S, Chaloin L.

J Med Chem. 2015 Dec 24;58(24):9680-96. doi: 10.1021/acs.jmedchem.5b01616. Epub 2015 Dec 7.

PMID:
26599519
23.

Use of designed experiments for the improvement of pre-analytical workflow for the quantification of intracellular nucleotides in cultured cell lines.

Machon C, Bordes C, Cros-Perrial E, Clement Y, Jordheim LP, Lanteri P, Guitton J.

J Chromatogr A. 2015 Jul 31;1405:116-25. doi: 10.1016/j.chroma.2015.05.069. Epub 2015 Jun 6.

PMID:
26094139
24.

Cell proliferation and drug sensitivity of human glioblastoma cells are altered by the stable modulation of cytosolic 5'-nucleotidase II.

Cividini F, Cros-Perrial E, Pesi R, Machon C, Allegrini S, Camici M, Dumontet C, Jordheim LP, Tozzi MG.

Int J Biochem Cell Biol. 2015 Aug;65:222-9. doi: 10.1016/j.biocel.2015.06.011. Epub 2015 Jun 14.

PMID:
26079827
25.

Determination of the enzymatic activity of cytosolic 5'-nucleotidase cN-II in cancer cells: development of a simple analytical method and related cell line models.

Jordheim LP, Puy JY, Cros-Perrial E, Peyrottes S, Lefebvre I, Périgaud C, Dumontet C.

Anal Bioanal Chem. 2015 Jul;407(19):5747-58. doi: 10.1007/s00216-015-8757-4. Epub 2015 May 22.

PMID:
25998135
26.

Cytosolic 5'-nucleotidase II interacts with the leucin rich repeat of NLR family member Ipaf.

Cividini F, Tozzi MG, Galli A, Pesi R, Camici M, Dumontet C, Jordheim LP, Allegrini S.

PLoS One. 2015 Mar 26;10(3):e0121525. doi: 10.1371/journal.pone.0121525. eCollection 2015.

27.

The purine analog fludarabine acts as a cytosolic 5'-nucleotidase II inhibitor.

Cividini F, Pesi R, Chaloin L, Allegrini S, Camici M, Cros-Perrial E, Dumontet C, Jordheim LP, Tozzi MG.

Biochem Pharmacol. 2015 Mar 15;94(2):63-8. doi: 10.1016/j.bcp.2015.01.010. Epub 2015 Feb 2.

PMID:
25656700
28.

Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma.

Jordheim LP, Ribrag V, Ghesquieres H, Pallardy S, Delarue R, Tilly H, Haioun C, Jardin F, Demangel D, Salles GA, Dumontet C.

Haematologica. 2015 May;100(5):e204-6. doi: 10.3324/haematol.2014.120113. Epub 2015 Jan 30. No abstract available.

29.

Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.

Jordheim LP, Cros-Perrial E, Matera EL, Bouledrak K, Dumontet C.

Clin Exp Pharmacol Physiol. 2014 Oct;41(10):817-24. doi: 10.1111/1440-1681.12282.

PMID:
25115435
30.

Fully validated assay for the quantification of endogenous nucleoside mono- and triphosphates using online extraction coupled with liquid chromatography-tandem mass spectrometry.

Machon C, Jordheim LP, Puy JY, Lefebvre I, Dumontet C, Guitton J.

Anal Bioanal Chem. 2014 May;406(12):2925-41. doi: 10.1007/s00216-014-7711-1. Epub 2014 Mar 15.

PMID:
24633509
31.

Structure-activity relationships of β-hydroxyphosphonate nucleoside analogues as cytosolic 5'-nucleotidase II potential inhibitors: synthesis, in vitro evaluation and molecular modeling studies.

Meurillon M, Marton Z, Hospital A, Jordheim LP, Béjaud J, Lionne C, Dumontet C, Périgaud C, Chaloin L, Peyrottes S.

Eur J Med Chem. 2014 Apr 22;77:18-37. doi: 10.1016/j.ejmech.2014.02.055. Epub 2014 Feb 24.

PMID:
24607586
32.

Therapeutic perspectives for cN-II in cancer.

Jordheim LP, Chaloin L.

Curr Med Chem. 2013;20(34):4292-303. Review.

PMID:
23992314
33.

Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?

Jordheim LP, Dumontet C.

Biomark Med. 2013 Aug;7(4):663-71. doi: 10.2217/bmm.13.48. Review.

PMID:
23905902
34.

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

Jordheim LP, Durantel D, Zoulim F, Dumontet C.

Nat Rev Drug Discov. 2013 Jun;12(6):447-64. doi: 10.1038/nrd4010. Review.

PMID:
23722347
35.

Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.

Tagoug I, Jordheim LP, Herveau S, Matera EL, Huber AL, Chettab K, Manié S, Dumontet C.

Clin Cancer Res. 2013 Jul 1;19(13):3556-66. doi: 10.1158/1078-0432.CCR-12-3134. Epub 2013 May 14.

36.

Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells.

Jordheim LP, Barakat KH, Heinrich-Balard L, Matera EL, Cros-Perrial E, Bouledrak K, El Sabeh R, Perez-Pineiro R, Wishart DS, Cohen R, Tuszynski J, Dumontet C.

Mol Pharmacol. 2013 Jul;84(1):12-24. doi: 10.1124/mol.112.082347. Epub 2013 Apr 11.

PMID:
23580445
37.

Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction.

Barakat KH, Jordheim LP, Perez-Pineiro R, Wishart D, Dumontet C, Tuszynski JA.

PLoS One. 2012;7(12):e51329. doi: 10.1371/journal.pone.0051329. Epub 2012 Dec 14.

38.

Nano-encapsulation of vitamin D3 active metabolites for application in chemotherapy: formulation study and in vitro evaluation.

Almouazen E, Bourgeois S, Jordheim LP, Fessi H, Briançon S.

Pharm Res. 2013 Apr;30(4):1137-46. doi: 10.1007/s11095-012-0949-4. Epub 2012 Dec 8.

PMID:
23225028
39.

Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening.

Jordheim LP, Marton Z, Rhimi M, Cros-Perrial E, Lionne C, Peyrottes S, Dumontet C, Aghajari N, Chaloin L.

Biochem Pharmacol. 2013 Feb 15;85(4):497-506. doi: 10.1016/j.bcp.2012.11.024. Epub 2012 Dec 7.

PMID:
23220537
40.

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.

Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL.

Gastroenterology. 2012 Sep;143(3):664-674.e6. doi: 10.1053/j.gastro.2012.06.006. Epub 2012 Jun 13.

PMID:
22705007
41.

Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin.

Jordheim LP, Ben Larbi S, Fendrich O, Ducrot C, Bergeron E, Dumontet C, Freney J, Doléans-Jordheim A.

Int J Antimicrob Agents. 2012 May;39(5):444-7. doi: 10.1016/j.ijantimicag.2012.01.019. Epub 2012 Mar 23.

PMID:
22445492
42.

Structural insights into the inhibition of cytosolic 5'-nucleotidase II (cN-II) by ribonucleoside 5'-monophosphate analogues.

Gallier F, Lallemand P, Meurillon M, Jordheim LP, Dumontet C, Périgaud C, Lionne C, Peyrottes S, Chaloin L.

PLoS Comput Biol. 2011 Dec;7(12):e1002295. doi: 10.1371/journal.pcbi.1002295. Epub 2011 Dec 8.

43.

Detecting differential allelic expression using high-resolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2.

Nguyen-Dumont T, Jordheim LP, Michelon J, Forey N, McKay-Chopin S; Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer, Sinilnikova O, Le Calvez-Kelm F, Southey MC, Tavtigian SV, Lesueur F.

BMC Med Genomics. 2011 May 11;4:39. doi: 10.1186/1755-8794-4-39.

44.

Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains.

Doléans-Jordheim A, Bergeron E, Bereyziat F, Ben-Larbi S, Dumitrescu O, Mazoyer MA, Morfin F, Dumontet C, Freney J, Jordheim LP.

Eur J Clin Microbiol Infect Dis. 2011 Oct;30(10):1249-56. doi: 10.1007/s10096-011-1220-3. Epub 2011 Apr 15.

PMID:
21494911
45.

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.

Jordheim LP, Sève P, Trédan O, Dumontet C.

Lancet Oncol. 2011 Jul;12(7):693-702. doi: 10.1016/S1470-2045(10)70244-8. Epub 2010 Dec 14. Review.

PMID:
21163702
46.

Further evidences for pharmacogenetic assessment of nucleoside analogue-treated patients.

Jordheim LP.

Leuk Res. 2011 Apr;35(4):429-30. doi: 10.1016/j.leukres.2010.10.012. Epub 2010 Nov 4. No abstract available.

PMID:
21051086
47.

Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868.

Jordheim LP, Plesa A, Dreano M, Cros-Perrial E, Keime C, Herveau S, Demangel D, Vendrell JA, Dumontet C.

Cancer Chemother Pharmacol. 2011 Jul;68(1):97-105. doi: 10.1007/s00280-010-1458-y. Epub 2010 Sep 16.

PMID:
20844879
48.

Liquid chromatographic methods for the determination of endogenous nucleotides and nucleotide analogs used in cancer therapy: a review.

Cohen S, Jordheim LP, Megherbi M, Dumontet C, Guitton J.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jul 15;878(22):1912-28. doi: 10.1016/j.jchromb.2010.05.016. Epub 2010 May 24. Review.

PMID:
20558114
49.

Bacterial deoxyribonucleoside kinases are poor suicide genes in mammalian cells.

Hébrard C, Cros-Perrial E, Clausen AR, Dumontet C, Piskur J, Jordheim LP.

Nucleosides Nucleotides Nucleic Acids. 2009 Nov;28(11):1068-75. doi: 10.1080/15257770903368393.

PMID:
20183574
50.

ADP ribosylation factor like 2 (Arl2) regulates breast tumor aggressivity in immunodeficient mice.

Beghin A, Belin S, Hage-Sleiman R, Brunet Manquat S, Goddard S, Tabone E, Jordheim LP, Treilleux I, Poupon MF, Diaz JJ, Dumontet C.

PLoS One. 2009 Oct 15;4(10):e7478. doi: 10.1371/journal.pone.0007478. Erratum in: PLoS One. 2009;4(11):10.1371/annotation/b0d43779-c9aa-44fe-a46d-71d7d2bc4a6a. Hage Sleiman, Rouba [corrected to Hage-Sleiman, Rouba].

Supplemental Content

Loading ...
Support Center